Data di Pubblicazione:
2018
Citazione:
Proprotein Convertase Subtilisin Kexin 9 Inhibitors / A. Pirillo, A.L. Catapano. - In: CARDIOLOGY CLINICS. - ISSN 0733-8651. - 36:2(2018 May), pp. 241-256. [10.1016/j.ccl.2017.12.006]
Abstract:
High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy. However, many patients cannot achieve the recommended LDL-C levels with current therapies. The discovery of the role of proprotein convertase subtilisin kexin 9 (PCSK9) in the regulation of plasma LDL-C levels suggested it as a potential pharmacologic target and led to the development of PCSK9 inhibitors for the management of LDL-C levels.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Alirocumab; Cardiovascular disease; Evolocumab; Hypercholesterolemia; LDL-C; Monoclonal antibodies; PCSK9; Proprotein convertase subtilisin kexin 9; Cardiology and Cardiovascular Medicine
Elenco autori:
A. Pirillo, A.L. Catapano
Link alla scheda completa: